April 22
2021
Anjum Shabbir
Anjum Shabbir
share
30th November 2020
Consumer, Health & Environment Covid-19 Institutional law

Op-Ed: “The Commission presents the EU’s Pharmaceutical Strategy: a paradigm shift?” by Sabrina Röttger-Wirtz

Presenting a Pharmaceutical Strategy for Europe in the middle of a pandemic has moved the European Commission into the spotlight in an area that otherwise is probably more of a niche topic in the EU law and policy community. Still, it should be clarified that the Pharmaceutical Strategy is not a reaction to the COVID-19 crisis: many of the action points contained in the Strategy can be traced back to the mission letter that President von der Leyen provided Commissioner Kyriakides with in September 2019. However, while reforms of the regulatory framework were to be expected, the COVID-19 pandemic has certainly been a catalyst for the Commission initiatives in this area.

The key action points of the Pharmaceutical Strategy are not s

×

Your privacy is important for us

We use cookies to improve the user experience. Please review privacy preferences.

Accept all Settings

Check our privacy policy and cookies policy.

Cookies